AbbVie announced the European Medicines Agency’s, or EMA, Committee for Medicinal Products for Human Use, orCHMP, recommended the approval of upadacitinib, 45 mg and 15 mg and 30 mg for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ABBV:
- AbbVie, Capsida announce expanded genetic medicines for eye diseases pact
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- AbCellera price target lowered to $32 from $40 at BMO Capital
- AbbVie downgraded to Peer Perform on valuation at Wolfe Research
- AbbVie downgraded to Peer Perform from Outperform at Wolfe Research
